151 related articles for article (PubMed ID: 2667032)
1. [Application of multinuclear in vivo magnetic resonance spectroscopy in oncology].
Semmler W; Gückel F; Bachert-Baumann P; Lorenz WJ; van Kaick G
Radiologe; 1989 Jul; 29(7):330-5. PubMed ID: 2667032
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance spectroscopy applied to clinical oncology.
Leach MO
Technol Health Care; 1994 Dec; 2(4):235-46. PubMed ID: 7842308
[TBL] [Abstract][Full Text] [Related]
3. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy.
van Laarhoven HW; Punt CJ; Kamm YJ; Heerschap A
Crit Rev Oncol Hematol; 2005 Dec; 56(3):321-43. PubMed ID: 15982898
[TBL] [Abstract][Full Text] [Related]
4. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.
Muruganandham M; Alfieri AA; Matei C; Chen Y; Sukenick G; Schemainda I; Hasmann M; Saltz LB; Koutcher JA
Clin Cancer Res; 2005 May; 11(9):3503-13. PubMed ID: 15867253
[TBL] [Abstract][Full Text] [Related]
5. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
[TBL] [Abstract][Full Text] [Related]
6. [Fundamentals and technical aspects of magnetic resonance spectroscopy in relation to patients].
Gückel F; Bachert-Baumann P; Semmler W
Radiologe; 1989 Jul; 29(7):322-9. PubMed ID: 2667031
[TBL] [Abstract][Full Text] [Related]
7. Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.
Sterin M; Cohen JS; Mardor Y; Berman E; Ringel I
Cancer Res; 2001 Oct; 61(20):7536-43. PubMed ID: 11606391
[TBL] [Abstract][Full Text] [Related]
8. MR spectroscopy in clinical research.
Henriksen O
Acta Radiol; 1994 Mar; 35(2):96-116. PubMed ID: 8172753
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance spectroscopy and imaging methods for measuring tumour and tissue oxygenation.
McCoy CL; McIntyre DJ; Robinson SP; Aboagye EO; Griffiths JR
Br J Cancer Suppl; 1996 Jul; 27():S226-31. PubMed ID: 8763886
[TBL] [Abstract][Full Text] [Related]
10. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
11. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
[TBL] [Abstract][Full Text] [Related]
12. 31P-magnetic resonance spectra of ovarian cancer cells exposed to chemotherapy within a three-dimensional Matrigel construct.
Abramov Y; Carmi S; Cohen JS; Anteby SO; Ringel I
Oncol Rep; 2012 Aug; 28(2):735-41. PubMed ID: 22581188
[TBL] [Abstract][Full Text] [Related]
13. Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment: 31P, 23Na, and 1H MRS studies of three models of pancreatic cancer.
Kaplan O; Kushnir T; Askenazy N; Knubovets T; Navon G
Cancer Res; 1997 Apr; 57(8):1452-9. PubMed ID: 9108445
[TBL] [Abstract][Full Text] [Related]
14. Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders.
Soares JC; Krishnan KR; Keshavan MS
Depression; 1996; 4(1):14-30. PubMed ID: 9160650
[TBL] [Abstract][Full Text] [Related]
15. High resolution nuclear magnetic resonance spectroscopy in clinical biology: application in oncology.
de Certaines JD
Anticancer Res; 1996; 16(3B):1325-31. PubMed ID: 8694498
[TBL] [Abstract][Full Text] [Related]
16. Observation of intramyocellular lipids by 1H-magnetic resonance spectroscopy.
Boesch C; Kreis R
Ann N Y Acad Sci; 2000 May; 904():25-31. PubMed ID: 10865706
[TBL] [Abstract][Full Text] [Related]
17. In vivo 31P MRS in new antineoplastic agents evaluation on experimental tumor models.
Le Moyec L; Naruse S; Higuchi T; Hirakawa K; Watari H; de Certaines JD; Roques BP
Cancer Biochem Biophys; 1988 Jul; 10(1):31-45. PubMed ID: 2465078
[TBL] [Abstract][Full Text] [Related]
18. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
[TBL] [Abstract][Full Text] [Related]
19. [Prospects for the application of 31-phosphorus NMR to the surveillance of anticancer treatment].
Le Moyec L; Benoist L; de Certaines J
Bull Cancer; 1985; 72(6):506-15. PubMed ID: 3912015
[TBL] [Abstract][Full Text] [Related]
20. Association between cortical metabolite levels and clinical manifestations of migrainous aura: an MR-spectroscopy study.
Schulz UG; Blamire AM; Corkill RG; Davies P; Styles P; Rothwell PM
Brain; 2007 Dec; 130(Pt 12):3102-10. PubMed ID: 17956910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
